288 related articles for article (PubMed ID: 33073049)
1. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms.
Al-Toubah T; Cives M; Strosberg J
Transl Gastroenterol Hepatol; 2020; 5():54. PubMed ID: 33073049
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
Weber MM; Fottner C
Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
[TBL] [Abstract][Full Text] [Related]
3. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
Garcia-Alvarez A; Cubero JH; Capdevila J
Curr Oncol Rep; 2022 Apr; 24(4):451-461. PubMed ID: 35171460
[TBL] [Abstract][Full Text] [Related]
4. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
Regalla DKR; Deep O; Paluri RK
Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkers.
Multone E; La Rosa S; Sempoux C; Uccella S
Virchows Arch; 2024 May; ():. PubMed ID: 38771338
[TBL] [Abstract][Full Text] [Related]
6. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio N; Abdel-Rahman O
Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms.
Koumarianou A; Kaltsas GA; Chatzellis E; Kyriakopoulos G; Kolomodi D; Alexandraki KI
Endocrine; 2021 Jul; 73(1):232-239. PubMed ID: 33544352
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
Fanciulli G; Modica R; La Salvia A; Campolo F; Florio T; Mikovic N; Plebani A; Di Vito V; Colao A; Faggiano A;
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010987
[TBL] [Abstract][Full Text] [Related]
10. "Present and future of immunotherapy in Neuroendocrine Tumors".
Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
Copur MS; Vargas L; Wedel W; Merani S; Cushman-Vokoun A; Drincic A
Oncology (Williston Park); 2020 Dec; 34(12):548-552. PubMed ID: 33395496
[TBL] [Abstract][Full Text] [Related]
12. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
Klöppel G
Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
[TBL] [Abstract][Full Text] [Related]
14. Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need.
Ramage JK; Valle JW; Nieveen van Dijkum EJM; Sundin A; Pascher A; Couvelard A; Kloeppel G; ;
Neuroendocrinology; 2019; 108(1):45-53. PubMed ID: 30219817
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.
Sultana Q; Kar J; Verma A; Sanghvi S; Kaka N; Patel N; Sethi Y; Chopra H; Kamal MA; Greig NH
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568540
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
18. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
